
|Articles|February 1, 2004
Phase III under way
New York - Adjuvant therapy with a macrophage-activating growth factor appears to prolong survival in high-risk melanoma, Lynn E. Spitler, M.D., said.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
2
Once-Daily Zasocitinib Rivals Injectable Biologics for Skin Clearance, Phase 3 Data Show
3
Moving Past Dermal Filler Trends to Focus on Healthy Skin Aging
4
Oral STAT6 Degrader KT-621 Shows Biologic-Comparable Activity in Atopic Dermatitis
5














